Yahoo Finance A Cue Biopharma, Inc. (NASDAQ:CUE) insider increased their holdings by 6.5% last year
Looking at Cue Biopharma, Inc.'s (NASDAQ:CUE ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.
While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.
View our latest analysis for Cue Biopharma
The Last 12 Months Of Insider Transactions At Cue Biopharma
In the last twelve months, the biggest single purchase by an insider was when CEO & Director Daniel Passeri bought US$50k worth of shares at a price of US$14.72 per share. That means that an insider was happy to buy shares at above the current price of US$4.01. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Daniel Passeri was the only individual insider to buy shares in the last twelve months.
The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
Cue Biopharma is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Insider Ownership
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data suggests Cue Biopharma insiders own 3.2% of the company, worth about US$4.6m. I generally like to see higher levels of ownership.
So What Do The Cue Biopharma Insider Transactions Indicate?
It doesn't really mean much that no insider has traded Cue Biopharma shares in the last quarter. On a brighter note, the transactions over the last year are encouraging. We'd like to see bigger individual holdings. However, we don't see anything to make us think Cue Biopharma insiders are doubting the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Cue Biopharma. While conducting our analysis, we found that Cue Biopharma has 3 warning signs and it would be unwise to ignore these.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
